NetworkNewsBreaks – CytoDyn Inc. (CYDY) Highligh
Post# of 148190
(Total Views: 319)
Posted On: 09/18/2018 4:42:52 PM
NetworkNewsBreaks – CytoDyn Inc. (CYDY) Highlighted in Corporate Summary from Leading Small Cap Media Portal
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) is the focus of a recently-released corporate summary from leading independent small cap media portal EmergingGrowth.com. The update details a number of topics from CytoDyn’s recent shareholder conference call, including highlights from the ongoing clinical development of its PRO 140 viral-entry inhibitor. The EmergingGrowth.com report notes that PRO 140 demonstrated a 93 percent suppression rate in 525mg trials after a six-week induction period. The summary further details CytoDyn’s new monotherapy trial, as well as the company’s recent efforts to generate capital through the sale of shares and the exploration of non-dilutive licensing pathways, particularly as they pertain to the company’s August acquisition of Prostagene and related licensing rights for “an extremely accurate prostate cancer prognostic that the competitor sells for $3,000.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company CytoDyn Inc. (OTCQB: CYDY) is the focus of a recently-released corporate summary from leading independent small cap media portal EmergingGrowth.com. The update details a number of topics from CytoDyn’s recent shareholder conference call, including highlights from the ongoing clinical development of its PRO 140 viral-entry inhibitor. The EmergingGrowth.com report notes that PRO 140 demonstrated a 93 percent suppression rate in 525mg trials after a six-week induction period. The summary further details CytoDyn’s new monotherapy trial, as well as the company’s recent efforts to generate capital through the sale of shares and the exploration of non-dilutive licensing pathways, particularly as they pertain to the company’s August acquisition of Prostagene and related licensing rights for “an extremely accurate prostate cancer prognostic that the competitor sells for $3,000.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼